

LIFE SCIENCES CONSULTANT & REGISTERED REPRESENTATIVE

CAPABILITIES

For Institutional Investors Use Only



DISCLOSURE STATEMENT

This presentation, including without limitation any information, estimates or projections contained herein or made in connection with this presentation, either in writing or orally or other format, (this "Presentation") is being furnished by or on behalf of The Translational Genomics Research Institute ("Company"). Any information contained in this Presentation is for informational purposes only and has not been independently verified. The Presentation may contain confidential and/or proprietary information and is provided for the exclusive use of the recipient and may not be reproduced, provided or disclosed to others, or used for any other purpose, without written authorization by S. Jordan Associates and the Company, and upon request must be returned to the Company or S. Jordan Associates.

S. Jordan Associates is not a Registered Investment Advisor, Broker/Dealer, Financial Analyst, Financial Bank, Securities Broker or Financial Planner, and any recipient of this Presentation acknowledges and agrees that S. Jordan Associates is not acting, nor is required to act, in any such capacity in connection with any transaction involving the Company pertaining to the matters contained herein. This Presentation is not intended to be and does not constitute financial advice or any other advice, is general in nature and not specific to any recipient. Recipients are responsible for their own investment research and investment decisions. Recipients should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained on this Presentation constitutes a solicitation, recommendation, endorsement, or offer by the Company or S. Jordan Associates or any of their affiliates or any third party service provider to buy or sell any securities or other financial instruments in this or in any other jurisdiction. This Presentation does not address the circumstances of any particular individual or entity. S. Jordan Associates is not a fiduciary by virtue of any person's use of or access to this Presentation or the information contained herein. Recipients alone assume the sole responsibility of evaluating the merits and risks associated with the use of any information or other content in this Presentation before making any decisions based on such information or other content.

The Company, S. Jordan and Associates and their respective affiliates make no representation or warranty (express or implied) as to the accuracy or completeness of this Presentation and none of them will have any liability for any recipient's use of this Presentation or any other oral, written, or other communications transmitted to the recipient in the course of its evaluation of the Company, including without limitation, any improper use or defamatory, offensive, or illegal conduct of recipient or any other users. This Presentation is provided on an "as is" basis without warranties of any kind, either express or implied, including but not limited to warranties of title or implied warranties of merchantability or fitness for a particular purpose. The disclaimers of liability contained herein apply to any damages or injury caused by any failure of performance, error, omission, interruption, deletion, defect, delay in operation or transmission, computer virus, communication line failure, theff or destruction or unauthorized access to, alteration of, or use of record, whether for breach of contract, tortious behavior, negligence, or under any other cause of action. In exchange for accessing this Presentation, recipients agree not to hold Company or S. Jordan Associates or any of their affiliates or any third-party service provider liable for any possible claim for damages arising from any use by or decision made by recipients based on information or other content made available to recipients in or through this Presentation.

Any recipient of this Presentation acknowledges and agrees that the Company, S. Jordan Associates and their affiliates are not liable for any use of this Presentation or reliance on any information from this Presentation. In no event will the Company, S. Jordan Associates or any of their affiliates be liable for any direct, indirect, incidental, special, or consequential damages (including but not limited to lost profits or trading losses) arising out of the use of or inability to use this Presentation. S. Jordan Associates and their affiliates do not endorse and are not responsible for the accuracy or reliability of any opinion, advice, information or statement on this Presentation.

This Presentation includes certain forward-looking statements, estimates and projections provided by, and with respect to the anticipated future performance of, the Company. In some cases, recipients can identify forward-looking statements by terminology such as "may", "estimates", "anticipates", "intends", "will", "should", "could", "expects", "believes", or "predicts". Such statements, estimates, and projections reflect various assumptions and elements of subjective judgment made by management concerning anticipated results, which are subject to business, economic, and competitive uncertainties and contingencies, many of which are beyond the control of the Company and which may or may not prove to be correct. This Presentation contains certain projected financial information that reflects management's projections as to anticipated future results based upon assumptions that are inherently uncertain, including assumptions as to the size of the market in which it competes, general industry conditions, and other factors. The assumptions are based upon management's judgment. As a result, no representation or warranty is made as to the feasibility of the projected financial information included in this Presentation. This Presentation is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction. Recipients should not regard this Presentation as a substitute for the exercise of their own judgment. The Company reserves the right to negotiate with one or more prospective third parties at any time, to terminate the further participation in the investigation and process by any party and to modify any procedures without giving advance notice or providing any reason thereof. The Company also reserves the right during the evaluation period to take any action, whether within or outside the ordinary course of business. Neither this Presentation nor its delivery to recipients shall constitute or be construed to be an offer to sell any securities of the Co

OPERATIONAL, BUSINESS DEVELOPMENT, AND BANKING EXPERIENCE



SCOTT JORDAN

FOUNDER / CEO https://www.linkedin.com/in/sjordan1/

- C-Level Operations Experience Chief Financial Officer (CFO) / Chief Business Officer (CBO) for private and public (NASDAQ) biotechnology companies leveraging non-dilutive funding, strategic partnerships, and the capital markets to advance development programs through proof-of-concept clinical studies
- Business Development / Investment Banking Expertise Over 30 years of structuring licensing
 agreements, closing Seed / Series rounds, cross-over financings, equity lines, and S1 / S3 shelf offerings
- Facilitated "Exits" via Mergers and Acquisition (M&A), Initial Public Offerings (IPOs), and Alternative Public Offerings (APOs - Special Purpose Acquisition Companies - SPAC / reverse mergers)



COREY MENDOZA

CHIEF MARKETING OFFICER https://www.linkedin.com/in/corevimendoza/

- A multiple award-winning Executive Producer, Writer, Director, Editor, Designer, Musician, and Marketing Strategist with over 25 years of professional experience. His expertise is in brand development, marketing & advertising, video and television production, and creative design.
- AWARDS:
- (5) Emmy Awards for "Minds of Medicine & "Vital Signs" (NATAS/Mid-Atlantic)
- (3) Telly Awards for "Best Production" in Television "Gold Coast Reality"
- (5) Axiem Awards for "Absolute eXcellence" in Digital Media
- (3) Silver Mic Awards for Advertising Commercials
- (2) MarCom Creative for regional Advertising Campaign



LINDA SU

VP, BUSINESS DEVELOPMENT

https://www.linkedin.com/in/linda-su-60491861/

• Works across various business development and operational areas including investor relations, intellectual property, finance, and capital raising

 Manages SJA Customer Relations Management (CRM) Cloud-Based Platform, Hubspot, targeting and engaging with potential strategic partners / investors on behalf of life science, medical device, and diagnostic clients





S. JORDAN ASSOCIATES (SJA) SERVICE OFFERINGS

NON-DILUTIVE FUNDING

S. Jordan Associates (SJA) is proficient identifying non-dilutive capital sources from Local, State (Cancer Prevention Research Institute of Texas - CPRIT) and Federally sponsored institutions (NIH / SBIR)

Guide clients through the application process and work collaboratively to implement best practices leading to successful awards



STRATEGIC ADVISORY/ BUSINESS DEVELOPMENT _

SJA engages with strategic partners seeking to outsource R&D via traditional and novel partnerships (option-to-buy / licensing, co-development). Services provided to emerging growth companies include:

- Assessing the competitive landscape and benchmarking against industry deal averages (upfront payments, royalties, milestones)
- Targeted outreach to large biopharmaceutical, diagnostic, and medical device companies managed within SJA's proprietary Customer Relationship Management (CRM) system
- Negotiating term sheets with prospective partners optimizing client deal metrics and shareholder return on investment (ROI)

PRIVATE COMPANY FINANCINGS

SJA exceeds client financing objectives by accessing the company's extensive network of institutional, angel groups, and alternative investors (accredited, family offices, hedge funds) to finance early to mid-stage biotech companies through major value inflection points / milestones

Effective at negotiating and closing Seed / Series rounds with institutional capital sources (venture capital, cross-over) and identifying / securing commitments from "Lead" sponsors pivotal to securing investor syndicates



"EXITS" / PUBLIC COMPANY FINANCINGS

SJA works diligently evaluating viable exit / public company financing vehicles including mergers and acquisitions, initial public offerings (IPOs), and alternative public offerings (reverse merger, SPAC) aligned with capital market conditions and company-specific attributes

Alternative Public Offerings (APOs):

Leverage strong relationships with sell-side banks and reverse merger / SPAC sponsors identifying public shells, submitting proposals to win auctions, and negotiating / closing term sheets on behalf of private companies seeking to list on public market exchanges (e.g. NASDAQ)





NON-DILUTIVE FINANCING – INOMAGEN THERAPEUTICS

- S. Jordan Associates (SJA) acted as financial advisor to Inomagen Therapeutics assisting with securing a \$3.67M NIH SBIR Fast Track Phase 1/2 Grant to develop a novel gene therapy for Atrial Fibrillation (AF)
- The award includes \$462,689 from the National Heart, Lung, and Blood Institute (NHLBI) to complete the 'Phase 1' segment of development which includes optimizing gene doses and electroporation parameters required for atrial gene delivery
- Upon successful completion of the Phase 1 segment, RTI eligible to receive an additional \$3,212,600 in NIH funding to carry out the 'Phase 2' segment, which will include determining optimal dose of gene therapy required to attenuate established electrical remodeling in AF

ABOUT INOMAGEN THERAPEUTICS, https://inomagen.com

 Inomagen Therapeutics, Inc. is a privately held biotechnology company with technology licensed from Northwestern University (NU) dedicated to delivering the promise of gene therapy for treating serious cardiovascular diseases such as atrial fibrillation



\$3.67M NIH SBIR Fast Track Grant inomagen Non-Dilutive Funding



PRIVATE COMPANY FINANCING – IMMUNOGENESIS

- S. Jordan Associates (SJA) acted as financial advisor to ImmunoGenesis assisting with raising a \$14.5M convertible note
- Lead investors include the founders of Chicago-based hedge funds (Magnetar Capital and Peak6), early-stage venture capitalists (BioAdvance, Texas Halo Fund) and secondary markets trading firm / crossover investor (Adit Ventures)

ABOUT IMMUNOGENESIS, https://www.immunogenesis.com/

- ImmunoGenesis formed to develop products from the lab of Dr. Michael A. Curran, Associate Professor, Department of Immunology at MD Anderson Cancer Center who worked closely with Nobel Laureate, Dr. James Allison, and is on the patent for CTLA-4 (cytotoxic T-lymphocyte-associated protein 4 – Ipilimumab / Yervoy) inhibition
 - Development programs to overcome immune resistance in "cold" tumors unresponsive to current checkpoint inhibition therapies which comprise the majority of all cancers






ACHIEVEMENTS: 2016 - 2020

NON-DILUTIVE FUNDING

- Secured awards from the Cancer Prevention Research Institute of Texas (CPRIT) resulting in ~\$35M of non-dilutive capital advancing three drug programs through Investigational New Drug (IND) enabling studies
- Leveraged non-dilutive capital during early stages of development to reach critical milestones resulted In subsequent financing rounds priced at higher valuations



STRATEGIC ADVISORY/ BUSINESS DEVELOPMENT

- Out-licensed South Korean rights to Salarius Pharmaceuticals / Iterion Therapeutics' lead compounds (Seclidemstat, Tegavivint) to HLB Lifesciences Co.
- Negotiated licensing terms including upfront payment, milestones, and royalties
- Established joint research committees monitoring progress and report findings to respective board members



PRIVATE COMPANY FINANCINGS

Raised development funding from academic Institutions, angel groups, and accredited / institutional investors (venture capital)



"EXITS" / PUBLIC COMPANY FINANCINGS

- Identified, awarded, negotiated, and closed a term sheet / public shell with Flex Pharma (FLRX) resulting in Salarius Pharmaceuticals listing on NASDAQ via a reverse merger in 2019
- Facilitated a \$10.9M equity line with Aspire Capital, a private, long-only investment fund focused on making investments in publicly traded companies
- Closed a \$11M \$1 offering with Ladenburg Thalmann funding Salarius through Phase 1 / 2 clinical milestones



Similar results are not guaranteed; based on investor demand and general market factors

TOMBSTONES: 2016 - 2020



Capital raises and licensing agreements facilitated as an executive {CFO / CBO} of Salarius Pharmaceuticals and Iterion Therapeutics



TRANSACTION HISTORY: 2005 - 2016







IMAGING

Capital raises, licensing agreements, and M&A / public offerings facilitated as a placement agent of S. Jordan Associates and Healthios Capital Markets.

Al/ Machine Learning – IQ500



SJA Partnered with IQ500 – Leader in AI / Machine Learning

IQ.500 connects Issuers, Investors and Strategic acquirors directly via an intelligent infrastructure that modernizes the entire private investment continuum from investment research and market analysis, to relationship mapping, networking, opportunity screening, communication, transaction management, due diligence, FAQ's, valuation, syndication, deal execution, benchmarking, performance measurement and exit planning.

Powered by machine learning which accurately predicts investments with 93% statistical precision, I.Q.500 seeks to transform the efficiency of the \$480 billion Venture Capital market by streamlining investment selection, risk management and outcome realization

Machine Learning Algorithm: Trained on 2 million VC transactions using 160 million analytical arrays across 800 dimensional vectors







IQ500 – Right Person, Right Deal, Right Time

WHICH INVESTORS ARE BEST FOR THE COMPANY?

Financial and strategic targets which are 93% likely to lead the Company's next transaction.




Image: set of the set of t

WHO DO WE CONTACT ? WHY? HOW?

Individual target contact affiliations. Direct, encrypted, "1:1" communication through MS Teams



WILL THERE BE INTEREST IN OUR DEAL?



Real—time, "in aggregate" data of activity by financial and strategic targets on Company listing



Mathematical Second Secon				Person Same
N STATE STATE STATE STATE STATE		tan i anti-tenso mate i muanto i tar		N/1078
Tang Mag Manual		Real Copie Tennes, 107		
n Non-set (% 1) Singer (% 1) Singer (% 1)		Name integration (see		
Dimension Performance Performance Main Performance Marine Main Performance Performance		test teste		
Image: second		Provide Section 1.		
Image Image Image Amount A A				
normania in anti- normania in anti- normania in anti- pertania in		Carrier and Anna - Anto Departs		
n i i i i i i i i i i i i i i i i i i i		1.0000		
anna y na h				
agatawa ya bagatawa				
hystom a logitum				
			1	
Applying hit we called hid by observate.	B-1-1-1	en hat we confid-find any relevant some.		ter-tent tent-tent terminet an an i

WHEN WILL THE DEAL CLOSE ?

KPI's, including strength of relationships; deal quality; likelihood of success; timing of close.



The company images/logos are being displayed for illustrative purposes and there is no guarantee a business transaction can be consummated.



IQ500 – Benefits for Issuers

Each Company listing on IQ500 features a range of deal experiences – solving the most important problems – and intended to support financial and strategic success throughout the business horizon.

HOW DO WE COMPARE ?

Peer Groups which place each Company among its closest "competitors", as established by investors and strategic participants on Company's target lists.



										6
Paar Bergunia	Sector	Frender	mit feering	feet Bank Gaat	Freed Stagetist Record (1968)	Lat Obeschute		Ang Tene Billion Billion (Pau)	14 Ban 8 Ban 9 Ban	an Aber Maria
Typic lithquids. In:	1.80	214	United Server		303	Harris (4, 1819)	10.9	64	28.3	
Halonia Marind Haldings ph-	4.85	2938	Indext		017	Advantage Inf. 2020	10.3		63	21
Dening Denie Media/Dalpheri Gu. Mi.	0.10	2111	Date		31.0	Primary 6, 2021	218	68	18.1	0
TWO DIVISION INC.	1.14	3TH	UPD-L'SIGN	3	10.0	DOMENT ST. 2020	-0.3	67	86.7	1
Contrast, SHIE	1.54	21.10	Farme	0	38.2	Overster 15, (N25	23.7	12	34	104
Gargenet Robotics SAG	1.84	0146	Energy		#.5	Jamany 4, 2020	18.2	14	5.4	184
MonFrequencies Inc.	1.84	397	Grinel Taxes	18	10.0	September 21, 2022	753	4.6	85.5	41
internation.	LH	2010	D-Ind Dates		-65.2	Depinder 5, 2022	-6.3	GH.	247	
INTERNAL MARKET, M.	0.84	213	No.	4	689.2	Occurber 35, 2820	.71.8	8.1	8.0	114
1805/10/545	1.54	21.00	Farms		95.5	pamany 17, (9010)	10.5	1.8		0
Annohistica/Darker-Daping: Do. 314	6.84	91-0	Daine		14.3	avy 15, 2420	963	64		0
Pharethese 38.	1.81	282	Louis	2	8.3	Januari, 2020	1.1	C.M.	1.8	24
Brat G Trubratingho LM.	1.24	2011	lanet.	3	-0.4	August 16, 2821	-0.3	3.2	1.0	10
matting to.	1.34	27.16	UNINTERN	2	380.2	December 1, (RID)	2.2	47	82	0
ApheniMetod. Nr.	1.54	2114	010473844	5	30.2	POwnton's (RIC)	90	1.8	8.2	
Catebor Orkellicianse inc.	1.54	0114	Lindust Status		245	18a/14,2010	- 63	1.6	2.6	4
Warning Dense MedicalDevice Dr., 144	0.84	2110	Daha		10.8	Admuny 18, 2822	1.4	6.6	8.7	2
Alternati Mexical Inc.	1.14	2107	United Dates		100.2	January 31, 2020	75.3	1.7	10.3	81
Nor Topolo, N.	6.84	219	UNHORN	- 0	10.2	Aquitit, DD	- 23	61	15.4	0
Number Paul Statistics	1.54	21.0	Indext							

WHAT IS HAPPENING IN OUR MARKET ?

WITH INVESTORS, BUYERS, PEERS ?






WHAT IS OUR VALUATION ? <u>EXIT PATH ?</u> Precedent Transactions, Public Comparables





MARKETING / HUBSPOT (CRM)







EMAIL MARKETING STRATEGY: OPTIMAL MESSAGE, AUDIENCE, TIME



Messaging content

General outreach / Brand recognition News update Event sign up Collaboration announcement Capital raising / Partnering



Targeted audience

Investors Strategic buyers Strategic partners Key opinion leaders Bankers



Timing

Highest open rate Highest engagement rate

Campaign specific time sensitivity



The <u>Translational Genomics Research Institute</u> (TGEN) and affiliate of City of Hope, a nonprofit medical research institute dedicated to conducting groundbreaking research, would like to schedule a meeting to discuss their novel pre-clinical CDK7 program.

CDK7 regulates cell cycle and super-enhancer dependent oncogene expression and is correlated with poor prognosis in many cancers (e.g. breast, gastric, hepatocellular, epilhelial ovarian, pancreatic cancers).



Below are links to the company's non-confidential deck and Calendly if you would like to schedule a call with TGEN to learn more about this promising small molecule program.



Regards, Scott Jordan S. Jordan Associates www.sjordanassociates.com scott@sjordanassociates.com



UTILIZING HUBSPOT DATA TOOLS (CRM) TO MEASURE SUCCESS



Metrics

Delivery rateDelivered

- Bounced
- Spam

Open rate

- Desktop vs. Mobile
- Email providers

Email view time

- Read
- Skimmed
- Glanced

HTML click map • Location of the clicks on the email

Clicks

 Optimization(s) for button, links, graphics

Clicked link(s) • Content clicked

Lead scoring

 Content engagement score for prioritization

Auto-advance life cycle stages

- Leads
- Scheduled a call
- Won / Lost


Dashboard

- Performance review
- Team discussion



DATA IS POWER

Follow up communications



Ensure conversations and activities connected to the contact database for continuous learning and optimization?



ALTERNATIVE PUBLIC OFFERINGS



ALTERNATIVE PUBLIC OFFERINGS (APO) TEAM

STRONG TRACK RECORD OF FACILITATING APO'S IN THE LIFE SCIENCES INDUSTRY

APO Webinar, "Reverse Mergers and SPACS:

Are Alternative Public Offerings the New Normal For Biotech's Going Public?" - March 18th, 2021 https://hubs.ly/H0JLhtK0



STEPHEN ALICANTI

Partner DLA Piper, LLC (US)



SCOTT JANSSEN

Managing Director

LS Associates

Part of the broader LifeSci Partner platform supporting over 200 clients with IR, PR, partnering / BD, and virtual CFO services



MIKE MONTGOMERY

Managing Partner

Effectus Group

Public filings, audit preparation, mergers and acquisitions, business combinations, financial due diligence, and integration



SCOTT JORDAN

Founder / CEO S. Jordan Associates

Raise private placements and concurrent financings, licensing / partnership agreements, M&A, and APOs – Reverse / SPAC



DAVID STRUPP

Co-CEO Ignyte Acquisition Corp.

Investment banker facilitating 18 reverse merger transactions and concurrent financings and SPAC Sponsor - Ignyte



APO SERVICES: INCEPTION TO CLOSING TRANSACTIONS

APO COORDINATION S. Jordan Associates manages APO Process on Behalf of SPAC Sponsors / Private Companies Including Facilitating Public Company Readiness and Capital Supporting APO Transactions Legal / Public Company Readiness Project Management / Close **Capital Support** Legal Finance / Interim C-Level Accounting / Controls **Investment Bankina** SPAC Sponsor / Banking > Audit readiness ➤ Evaluation and > Legal advice and > Forecasting and financial / > SPAC Sponsor (Ignyte cash flow modeling document preparation / implementation of financial Acquisition Corp) > S-4 prep (F Pages, MDA, Pro controls negotiation including Forma) > Capital raises includina > Introduction to SPAC and M&A. tax and securities > Recruiting and leading the venture capital (Series A>), reverse merger clients of > Internal controls law internal accounting and concurrent and cross-over Ladenburg Thalmann finance team members financings (PIPES), and public \succ Accurate, reliable and timely SEC disclosure and market offerinas KPI and financial reporting Investor and public relations periodic reporting > Introduction to SPACs, reverse strategies and leadership guidance merger sponsors > Term sheet neaotiations 'Virtual' Team **DAVID STRUPP STEPHEN ALICANTI** SCOTT JANSSEN **MIKE MONTGOMERY** SCOTT JORDAN LifeSci Effectus ADENBURG LS ASSOCIATES Group HALMANN IGNYTE 5. JORDAN ASSOCIATES



APO PUBLIC READINESS CHECKLIST

Strategic	Have you built an IPO or De-SPAC roadmap with specific subject matter experts, work stream, and milestones? Who is the project owner / manager and do they have experience with this complex process? Has the board reviewed the plan and key dates? Have you performed a Board "audit" to make sure you have the people, skills, and governance in place to lead a company into and operate effectively as a public company? Are the internal shareholders and experts on the Board held accountable for their portion of the project? Have you engaged a team of expert consultants to support the project (e.g. attorney's, financial and technical accounting, consultants, auditors, D&O insurance providers)? Have you prepared accurate, reliable, and timely financial and scientific reports that will be required as a public company? Do you have reliable forecasting and subsequent actual to forecast reporting?
Finance / Accounting	Reviewed monthly closing book process / gap analysis necessary? Team in place to implement financial planning and analysis including the review of budgt vs. actual processes? Audited financials? If not, has the company received quotations from potentail auditing firms? Company discussed with management / Board final selection of auditors? Company worked with auditors / director of finance from an accounting firm to complete the audit? Completed a 409A valuation that can be substantiated under PCAOB standards? Reviewed the cap table ensuring all supporting documentation in place including all financial transactions? Set up data base to collect company information such as contracts, stock option grants, financial statements for efficient audit process?
Capital Raise	Developed a plan and timeline for next financing? Completed an investor deck review by Investor Relations and financial experts ensuring synergistic with financial forecasts and budget? Reviewed 5 / 10-year financial plan and balance sheet? Reviewed a list of possible Series / Cross-over investors and selected a banker to assist with the process? Initiated the IPO / De-SPAC roadmap with estimated timelines, assigned workstreams to stakeholders and consultants?

APPENDIX #1- SJA PRIVATE PLACEMENT SERVICES AND TIMELINES



PRIVATE PLACEMENT SERVICE OFFERINGS

	¹ S. Jordan Associates (SJA)	Services	² Finalis / Marketplace	Services	³ IQ500	Services
	 SJA is a Chicago / Miami-based investment bank specializing in providing the following services for emerging growth biotechnology, medical device, and diagnostic companies including: Non-Dilutive Capital Private Placements M&A Alternative Public Offerings Strategic Advisory 		World's fastest growing deal making and management platform powered by the Company's "Marketplace" enabling issuers to raise capital through Finalis' broker dealer syndicate network which comprises over 200 registered representatives.		Connects Issuers, Investors and Strategic acquirors directly via an intelligent infrastructure that modernizes the entire private investment continuum: from investment research and market analysis, to relationship mapping, networking, opportunity screening, communication, transaction management, due diligence, FAQ's, valuation, syndication, deal execution, benchmarking, performance measurement and exit planning.	
Economics Terms						
Engagement Fee / Month	1					
>\$10,000	*	SJA Banking Engagement				
\$8,000 - \$10,000	*	SJA (+ Equity) - ⁴ Finalis Syndicate Manager (Optional)	*	⁵ Finalis Syndicate - Placement (Optional)	*	Finalis (Optional)
< \$8,000	*	Finalis Syndicate Manager	*	Finalis Syndicate - Placement	*	Finalis (Optional)
None						
Success Fee (%)	*	To be Negotiated	*	To be Negotiated	*	To be Negotiated
Term (Months)	*	4-6	*	4-6		Cancellable Monthly
Subscription Fees (\$)					*	\$1,000 / Month

FOOTNOTES

¹SJA Engagements - Terms and Conditions Contingent Upon Approved Engagement Following SJA Diligence Review

²Finalis Engagement - Terms and Conditions Contingent Upon Approved Engagement Following Finalis Diligence Review

³ AI Platform

⁴ SJA as Syndicate Manager - Oversee Finalis Investor Syndicate Activities

⁵ Finalis Syndicate - Consortium of Registered Representatives Under Agreement to Raise Capital on Behalf of Issuer



PRIVATE PLACEMENTS - TIMELINE

MONTH 1	MONTHS 2-4	MONTHS 5-6
PREPARATION		
 Review / Prepare Marketing Documents Executive Summary / Teaser Non-Confidential Deck Confidential Deck Supporting Documents Valuation Model Discounted Cash Flow (DCF) 'Comp' Analysis Finance Financial Statements Cap Table Securities / Legal SEC Filings: 506b / 506c Documents: Term Sheet, PPM Data Room Frame the Architecture Load Documents Set Permissions 	 Target Investors Based on Status of Fund and Match to Company Profile Status: Actively Investing in New Companies (Preference for Recently Raised Funds) Investing in Similar Company Modality: Small Molecules, Biologics, Gene- Cell Therapy Stage of Development: Pre / Clinical / Approved Security Profile / Range: Preferred / Round Size (\$M) Marketing / Outreach Referrals Email Linkedin Conferences Engagement Analytics / Reporting Opens / Clicks Viewed Deck Scheduled Calls 	 Diligence / Confidential Review CDAs Sent / Executed Data Room Access Confidential Management Presentations Negotiation of Terms Proposed Actual Sign Agreement Receipt of Funding Add Investor(s) to Cap Table Public Announcement

APPENDIX #2 - IPO VS. SPAC



INITIAL PUBLIC OFFERING (IPO) vs SPAC

Pro and Con Con	Pro	
	IPO	SPAC
Certainty of Pricing, Pre-Transaction Launch and Closing	Lower: "2" Step Process - From Closing of the Crossover to the Pricing of the Offering, Significant Risk Associated with Intrinsic (Pipeline News) and Extrinsic (Macro Issues) Events Creating Risk Around the Raise and Valuation	Higher: "1" Step Process - Ability for Crossover and De-SPAC to Close Simultaneously; Increased Certainty of Pricing / Closing Provided Deal Negotiated Behind "Closed Doors" Between SPAC Sponsor and Targeted Company
Timeline / Considerations for Going Public	Longer (~12+ Months): Extended Timeline of a Typical IPO Process Given Crossover and IPO Not Closed Simultaneously and Road Show Requirement for Pricing of the deal	Shorter (~3-6 Months): For a Merger Target, the Timeline for Pubilic Offering is shorter than a traditional IPO given "1" step process - De-SPAC / Crossover
Potential Liquidity Event for Existing Shareholders	No	Yes
Potential Liquidity Event for Existing Shareholders Potential Management Earn-Outs and Structuring Flexibility	No	Yes Yes: Merger Target Could Earn Future Equity Milestones if Pipeline Delivers More than the SPAC Sponsor Expected, or if Certain Price Targets Are Met
Potential Management Earn-Outs		Yes: Merger Target Could Earn Future Equity Milestones if Pipeline Delivers More than the SPAC



INITIAL PUBLIC OFFERING (IPO) vs SPAC

	IPO	SPAC
Valuation	Pro: Priced via a Multi-Day Book-Building Process with Multiple Investors Putting in their Orders Con's: IPO Pricing Largely Driven by the Pricing Appetite of a Few Large Accounts; Risk of Underpriced Public Offerings Resulting in Stock Price Increasing Post- Close Representing significant "Value "Left on the Table"	Pro's: Higher Valuation - SPAC Price Discovery is Largely a Direct Negotiation Between the SPAC Sponsor and the Target; Concurrent PIPE acts as an Important Source of Price Validation Supporting the Valuation Negotiated by the Sponsor Con's: Higher Valuations Negotiated to Offset Increased Dilution Associated with Sponsor Shares / Warrants; Limiting Number of Companies Eligible to Participate - Higher Enterprise Value Required to Transact
Dilution	Pro: No Dilution From Sponsor Shares / Warrants Con: Sell 25-35% in the Crossover Round + Sell Another 20-30% in the IPO + 'Greenshoe' Dilution	 Pro: Because SPACs Replace the Two-Step of Crossover and IPO, Valuations can Approach that of the IPO Itself Resulting in Less Total Dilution (10-15%) Adding Value to Existing Shareholders Con: Additional Dilution Associated with Sponsor Shares, Private Warrants and Public Warrants
Transaction Structure	Rigid Equity Financing Structure with Investors Receiving Preferred Stock, Liquidation Preferences, and Other Protections at Founder's Expense	Flexible Deal Structure With Earnouts Allows Management to Receive Additional Compensation Upon Company Performance
Crossover / Buy Side Allocations	Lower: Especially in IPOs that are Oversubscribed, Crossover / Buy Side Investors Oftentimes Receive Smaller Allocations	Higher: Significant Allocation of Capital to Invest Over Time Especially Meaningful to Large Investment Funds Seeing to Deploy Capital
Optimal Profile: Private Company		 Pipeline / Clinical News Flow over Next 1-3 Years Previously Raised \$25 - \$100M in Preferred Stock Financings (3) Access to Crossover Investors



INITIAL PUBLIC OFFERING (IPO) vs SPAC

	IPO	SPAC
Financial Disclosures – SPAC Allowable Disclosures Under PSLRA Review and Subject to Change	Historical Financial Statements Required Stemming From The Private Securities Litigation Reform Act (PSLRA); No Safe Harbor for Forward-Looking Statements	Pro: Safe Harbor for Forward-Looking Statements Applies Providing Companies with More Flexibility to Share Future Earnings Projections Making a Deal More Attractive Especially with Pre-Revenue Companies Con : There's an Emerging Class of Plaintiff Attorney's Looking at the space as a Result
Reduced Investor Risk	N/A	Reduced Investor Risk Given Shares are Redeemable and Oftentimes Receive a Free Warrant Which They Can Keep Even if Not Participating in the De-SPAC
Merger Target	N/A	With a Specific Valuation Mutually Agreed for the Merger, There's a Clear Timetable for Closing the Deal and Trading as a Public Company (the "de- SPAC" process); For a Merger Target, Both the Timeline to Being Public, as well as the Pre-Specified Scale of the Valuation and Capital Raise are Better "Controlled" in a SPAC Process
Post-Finance Outlook	Oftentimes Need to Conduct Several Financing Processes Within 8-12 Months Distracting Management from Company Operations	Public Company with Strong Institutional Investor Base and Access to Public Capital Markets Facilitating Management Focus on Operations
Liquidity	Existing Shareholders Generally Required to Wait Six Months From Closing of the IPO Prior to Selling Shares	Existing Shareholders (Sponsor) Generally Required to Wait One Year From Closing of the Business Combination (De-SPAC) Prior to Selling Shares

APPENDIX #3 - ALTERNATIVE PUBLIC OFFERING (APO) CASE STUDY



SALARIUS PHARMACEUTICALS REVERSE MERGES INTO FLEX PHARMA

- Salarius Pharmaceutical (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced closing a merger with Flex Pharma, Inc.'s wholly owned subsidiary on July 19, 2019
- The newly combined company focused on the continued development of Salarius' clinical pipeline, which targets rare, orphan cancers with lead compound, Seclidemstast, a LSD1 inhibitor (epigenetics validated target)
- Healthios Capital Markets (now Third500 <u>https://www.third500.com/</u>) served as financial advisor in the transaction to Salarius Pharmaceuticals and Wedbush PacGrow advised Flex Pharma

Allocation Percentage - from Summary of Proposed Terms	\$M	%	
Flex Enterprise Value - "Shell"	\$7.2		
Flex Cash at Close	\$3.1		FLEXPharma
Flex Total Fair Value	\$10.3		
Salarius Total Fair Value	\$36.0		Salarius PHARMACEUTICALS The Cancer Epigenetics Company
Total Fair Value of Newco	\$46.3		\$46.3M Deal Value
Allocation Percentage			
Flex		22.3%	
Salarius		77.7%	
		, , ,, ,0	



TIMELINE / MILESTONES FROM INCEPTION TO REVERSE MERGER CLOSING

FLEXPharma	2018			20	19	Salarius PHARMACEUTICALS NASDAQ: SLR	X	2020
1Q - 2Q	3Q	4Q	10	2Q	3Q	4Q	1Q	2Q
 Established Connections with Investment Banks via Buy Side / Conferences Banker Introductions to NASDAQ Shells - Auctions Salarius Submitted Proposals to Banks Reverse Merger Bids Declined - MIRNA / Anthera 	 Introduction to Ohr / Flex Signed CDAs / Completed Diligence Initiated Negotiations Exchange Ratio / Cash at Close Awarded Ohr / Flex Shells Flex Shell Selected, > Net Cash at Close Financial Audit Completed 	 Received Board Approval - Merger with Flex Pharma Closed \$6.4M Series A Financing Negotiated Merger Agreement / Term Sheet Fairness Opinion Completed by Third500 (Investment Bank) Exchange Ratio 77.7% Salarius / 22.3% Flex 	 Board Resolutions Approved Including Merger Agreement, Reverse Stock Split, Name Change Formation of Merger Sub Submitted SEC / NASDAQ Applications Including S-4 Filing - Financial Statements, Risk Factors, MD&A 	 Responded to NASDAQ Comment Letter S-4 declared effective by SEC Obtained CUSIP S-3 Shelf Offering Remained Active Met NASDAQ Deadlines for Shareholder Equity / Minimum Price Per Share Bid Price (>\$1.00) 	 Secured Stockholder Votes in Favor of Merger Prospectus Supplement / Comfort Letter Reverse Split: 25:1 Closed / Announced Merger Listing on NASDAQ Sold Flex Subsidiary - HOTSHOT Filed 8-K/A Launched S3 Offering 	 Secured \$10.9M Equity line from Aspire Capital From Salarius' S-3 Shelf Registration Drew Down \$2.6M in Aggregate Proceeds from Equity Line Ladenburg Selected for S1 Offering Held Annual Meeting of Stockholders 	 Filed S-1 Offering Raised \$11M From \$1 Prior to COVID Crisis Funding SLRX Through Read-Out of Clinical Milestones in 2021 (Ewing Sarcoma Phase 1 / 2 Study) Filed 4Q 10Q and 2019 10K Received Fast Track Designation 	 Filed 1Q 2020 10Q Launched Initiatives to Drive Trading Volume / Stock Price Purchases of Salarius Stock by Retail and Institutional Investors in Secondary Market – Hired IR / PR Firm Filed Proxy Announced Annual Meeting

Similar results are not guaranteed; based on investor demand and general market factors.



S. JORDAN ASSOCIATES

Life Sciences Consultant & Registered Representative

SCOTT JORDAN Founder / CEO

512 N. McClurg #4604 Chicago, IL 60611

312-451-6210 scott@sjordanassociates.com www.sjordanassociates.com



() @

@sjordanassociat

